JOHNSON & JOHNSON
Known title: 10% OwnerCIK: 0000200406
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Johnson & Johnson: Key Takeaways for Long-Term Investors. Recent coverage highlighted three takeaways for long‑term investors in Johnson & Johnson. The article notes the company's steady dividend yield of about 3.1% and its diversified healthcare portfolio. It also points to a relatively high price‑to‑earnings multiple, suggesting expectations of continued growth. These points are relevant as the stock trades near a long‑standing support level.
Transaction History
| CVRX | ▼ Sell | Open Market | 6,337 | $64K | 11/26/2025 | View on chart |
| CVRX | ▼ Sell | Open Market | 2,200 | $22K | 11/24/2025 | View on chart |
| CVRX | ▼ Sell | Open Market | 500 | $5K | 11/21/2025 | View on chart |
| CVRX | ▼ Sell | Open Market | 1,000 | $10K | 11/12/2025 | View on chart |
| CVRX | ▼ Sell | Open Market | 200 | $2K | 11/7/2025 | View on chart |
| CVRX | ▼ Sell | Open Market | 52,332 | $534K | 11/6/2025 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 300 | $71 | 2/29/2024 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 23 | $5 | 2/29/2024 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 489 | $116 | 2/29/2024 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 584 | $138 | 2/29/2024 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 158 | $37 | 2/29/2024 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 189 | $45 | 2/29/2024 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 165 | $39 | 2/29/2024 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 118 | $28 | 2/29/2024 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 71 | $17 | 2/29/2024 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 442 | $524 | 2/29/2024 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 142 | $168 | 2/29/2024 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 252 | $997 | 2/29/2024 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 79 | $406 | 2/29/2024 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 85 | $20 | 2/29/2024 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 758 | $180 | 2/29/2024 | View on chart |
| CVRX | ▼ Sell | Other | 607,725 | $96K | 2/16/2024 | View on chart |
| CVRX | ▼ Sell | Open Market | 3,725 | $96K | 2/16/2024 | View on chart |
| JNJ | ▼ Sell | Other | 1,533,830,450 | — | 8/23/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
CVRx Appoints John Landry as CFO
CVRx announced that John Landry will become chief financial officer, effective Oct. 12, replacing Jared Oasheim. The change follows a routine leadership transition and may bring new financial oversight to the company. The appointment is noted by market watchers but does not alter the current trading range or technical signals. Investors can monitor how the new CFO’s approach aligns with the company’s financial goals.
CVRx Appoints John Landry as CFO. CVRx announced that John Landry will become chief financial officer, effective Oct. 12, replacing Jared Oasheim. The change follows a routine leadership transition and may bring new financial oversight to the company. The appointment is noted by market watchers but does not alter the current trading range or technical signals. Investors can monitor how the new CFO’s approach aligns with the company’s financial goals.